Literature DB >> 9546570

Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association.

L S Goldman1, M Genel, R J Bezman, P J Slanetz.   

Abstract

OBJECTIVE: To deal with public and professional concern regarding possible overprescription of attention-deficit/hyperactivity disorder (ADHD) medications, particularly methylphenidate, by reviewing issues related to the diagnosis, optimal treatment, and actual care of ADHD patients and of evidence of patient misuse of ADHD medications. DATA SOURCES: Literature review using a National Library of Medicine database search for 1975 through March 1997 on the terms attention deficit disorder with hyperactivity, methylphenidate, stimulants, and stimulant abuse and dependence. Relevant documents from the Drug Enforcement Administration were also reviewed. STUDY SELECTION: All English-language studies dealing with children of elementary school through high school age were included. DATA EXTRACTION: All searched articles were selected and were made available to coauthors for review. Additional articles known to coauthors were added to the initial list, and a consensus was developed among the coauthors regarding the articles most pertinent to the issues requested in the resolution calling for this report. Relevant information from these articles was included in the report. DATA SYNTHESIS: Diagnostic criteria for ADHD are based on extensive empirical research and, if applied appropriately, lead to the diagnosis of a syndrome with high interrater reliability, good face validity, and high predictability of course and medication responsiveness. The criteria of what constitutes ADHD in children have broadened, and there is a growing appreciation of the persistence of ADHD into adolescence and adulthood. As a result, more children (especially girls), adolescents, and adults are being diagnosed and treated with stimulant medication, and children are being treated for longer periods of time. Epidemiologic studies using standardized diagnostic criteria suggest that 3% to 6% of the school-aged population (elementary through high school) may suffer from ADHD, although the percentage of US youth being treated for ADHD is at most at the lower end of this prevalence range. Pharmacotherapy, particularly use of stimulants, has been extensively studied and generally provides significant short-term symptomatic and academic improvement. There is little evidence that stimulant abuse or diversion is currently a major problem, particularly among those with ADHD, although recent trends suggest that this could increase with the expanding production and use of stimulants.
CONCLUSIONS: Although some children are being diagnosed as having ADHD with insufficient evaluation and in some cases stimulant medication is prescribed when treatment alternatives exist, there is little evidence of widespread overdiagnosis or misdiagnosis of ADHD or of widespread overprescription of methylphenidate by physicians.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9546570     DOI: 10.1001/jama.279.14.1100

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  184 in total

Review 1.  Non-stimulant treatments for ADHD.

Authors:  J Biederman; T Spencer
Journal:  Eur Child Adolesc Psychiatry       Date:  2000       Impact factor: 4.785

Review 2.  Evidence based management of attention deficit hyperactivity disorder.

Authors:  J P Guevara; M T Stein
Journal:  BMJ       Date:  2001-11-24

Review 3.  Attention deficit hyperactivity disorder.

Authors:  J P Guevara; M T Stein
Journal:  West J Med       Date:  2001-09

Review 4.  Early pathogenic care and the development of ADHD-like symptoms.

Authors:  Brigitte Dahmen; Vanessa Pütz; Beate Herpertz-Dahlmann; Kerstin Konrad
Journal:  J Neural Transm (Vienna)       Date:  2012-06-02       Impact factor: 3.575

5.  The relationship between past-year drinking behaviors and nonmedical use of prescription drugs: prevalence of co-occurrence in a national sample.

Authors:  Sean Esteban McCabe; James A Cranford; Carol J Boyd
Journal:  Drug Alcohol Depend       Date:  2006-04-18       Impact factor: 4.492

6.  Incidence and prevalence of drug-treated attention deficit disorder among boys in the UK.

Authors:  Hershel Jick; James A Kaye; Corri Black
Journal:  Br J Gen Pract       Date:  2004-05       Impact factor: 5.386

7.  School-based health centers: cost-benefit analysis and impact on health care disparities.

Authors:  Jeff J Guo; Terrance J Wade; Wei Pan; Kathryn N Keller
Journal:  Am J Public Health       Date:  2010-07-15       Impact factor: 9.308

Review 8.  Endocrine disrupters: a review of some sources, effects, and mechanisms of actions on behaviour and neuroendocrine systems.

Authors:  C A Frye; E Bo; G Calamandrei; L Calzà; F Dessì-Fulgheri; M Fernández; L Fusani; O Kah; M Kajta; Y Le Page; H B Patisaul; A Venerosi; A K Wojtowicz; G C Panzica
Journal:  J Neuroendocrinol       Date:  2012-01       Impact factor: 3.627

9.  Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults.

Authors:  John S Markowitz; Arthur B Straughn; Kennerly S Patrick; C Lindsay DeVane; Linda Pestreich; James Lee; Yanfeng Wang; Rafael Muniz
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

10.  Metabolism, distribution and elimination of lisdexamfetamine dimesylate: open-label, single-centre, phase I study in healthy adult volunteers.

Authors:  Suma M Krishnan; Michael Pennick; Jeffrey G Stark
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.